Human IL-1 beta ELISA Ready-SET-Go!

Human IL-1 beta ELISA Ready-SET-Go! (2nd Generation)

Also known as: Interleukin-1 beta

RUO: For Research Use Only. Not for use in diagnostic procedures.

Description: This Human IL-1 beta Ready-SET-Go! (2nd Generation) ELISA Set contains the necessary reagents, standards, buffers and diluents for performing quantitative enzyme-linked immunosorbent assays (ELISA). This ELISA set is specifically engineered for accurate and precise measurement protein levels from samples including serum, plasma, and supernatants from cell cultures. This ELISA will recognize the cleaved mature form and uncleaved pro-form of Human IL-1 beta. This second generation kit has increased sensitivity with a range from 2-150 pg/mL.

IL-1 beta is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. It is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1 beta into the active 17 kDa protein requires the activation of inflammasomes, which are multi-protein complexes that respond to pathogens, stress conditions, and other danger signals. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1 beta. IL-1 beta lacks a signal sequence peptide for classical ER/Golgi pathway and is instead secreted alongside caspase-1 via an alternate and incompletely understood mechanism. IL-1 beta signals through two receptors, IL-1RI and IL-1RII, both of which are shared with IL-1 alpha. These cytokines play important roles in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses. Their activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. Elevated levels of IL-1 beta have been associated with many chronic inflammatory conditions, giving IL-1RA or IL-1 beta neutralizing antibodies potential therapeutical value.